REC-617 (CDK7 inhibitor)
Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary): company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
REC-617 is a CDK7 inhibitor from Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary). It is being developed for advanced solid tumors. ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT05985655. The AI role named in the source is molecule design. Registry records: NCT05985655, Phase 1/2, recruiting, updated Aug 13, 2026. About the company, based in United States: Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design. The latest dated source is from Aug 13, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary)
- Indication
- Advanced solid tumors
- Therapeutic area
- Oncology
- AI role
- Molecule design
- Phase in the source
- Phase 1/2, as of Aug 13, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Company
“Designed using our AI-powered OS platform, REC-617”
Trial records
- NCT05985655 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
NCT05985655 first posted on ClinicalTrials.gov
-
ClinicalTrials.gov record: Phase 1/2
-
NCT05985655 record updated
Phase 1/2, Recruiting
About Recursion Pharmaceuticals
Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design.
Spot an error? Tell me and I'll fix it.